The FDA Has Removed The Partial Clinical Hold On Vigil Neuroscience's Ongoing Phase 1 Trial Of VG-3927, Based On Complete Response The Company Submitted, Complete Data Is Expected In The First Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
The FDA has lifted the partial clinical hold on Vigil Neuroscience's Phase 1 trial of VG-3927 after the company submitted a complete response. Full data from the trial is expected in Q1 2025.
September 17, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA has removed the partial clinical hold on Vigil Neuroscience's Phase 1 trial of VG-3927, indicating progress in their clinical development. This could positively impact investor sentiment.
The removal of the FDA's partial clinical hold suggests that Vigil Neuroscience has addressed the agency's concerns, allowing the trial to proceed. This is a positive development for the company, potentially boosting investor confidence and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100